Edition:
India

People: Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

3.06EUR
16 Sep 2019
Change (% chg)

€0.06 (+2.00%)
Prev Close
€3.00
Open
€2.99
Day's High
€3.06
Day's Low
€2.99
Volume
21,426
Avg. Vol
39,182
52-wk High
€3.93
52-wk Low
€2.93

Lawrence, David 

Mr. David Lawrence has been Chief Financial Officer, Member of the Management Board of VALNEVA since August 1, 2017. He has over 25 years of experience in the pharmaceutical, biotech and vaccine industries, with a proven international track record in mid-sized to large companies and small biotech start-ups. His tested leadership experience as a CFO in the Lifesciences sector spans across finance and accounting, mergers and acquisitions, fund raising and investor relations. He served as CFO in a dual-listed (LSE and NASDAQ) vaccine biotech company (Acambis plc, acquired by sanofi in 2008) and was Vice President of Finance & Business Development for Chiron Vaccines, a division of Chiron Corporation which was acquired by Novartis in 2005. Prior to these roles, he held senior finance positions at GlaxoSmithKline including Vice President of Financial Management in Research and Development. He is currently also Board Member at Valneva Sweden AB, Vaccines Holdings Sweden and Valneva Canada Inc., among others.

Basic Compensation

Total Annual Compensation, EUR 316,432
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR 56,194
Fiscal Year Total, EUR 372,626

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --